Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Data sharing in clinical trials: An experience with two large cancer screening trials.

Zhu CS, Pinsky PF, Moler JE, Kukwa A, Mabie J, Rathmell JM, Riley T, Prorok PC, Berg CD.

PLoS Med. 2017 May 23;14(5):e1002304. doi: 10.1371/journal.pmed.1002304. eCollection 2017 May.

2.

PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.

Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, Ragard L, Hermansen S, Yu K, Pinsky P, Prorok PC, Freedman ND, Hoover RN.

Rev Recent Clin Trials. 2015;10(3):238-45. Review.

3.

Data Processing and Analytic Support in the PLCO Cancer Screening Trial.

Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):233-7. Review.

PMID:
26238116
4.

Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.

Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V.

Urol Oncol. 2016 Apr;34(4):167.e9-16. doi: 10.1016/j.urolonc.2015.10.011. Epub 2015 Nov 18.

PMID:
26602092
5.

Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST).

Kramer BS, Berg CD, Aberle DR, Prorok PC.

J Med Screen. 2011;18(3):109-11. doi: 10.1258/jms.2011.011055. No abstract available.

6.

Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial.

Bazzi L, Lamerato LE, Varner J, Shambaugh VL, Cordes JE, Ragard LR, Marcus PM.

Rev Recent Clin Trials. 2015;10(3):200-5. Review.

PMID:
26238207
7.

The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.

Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, Gohagan JK.

J Natl Cancer Inst. 2013 Nov 20;105(22):1684-93. doi: 10.1093/jnci/djt281. Epub 2013 Oct 10. Review.

8.

Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, Hazelton WD, Plevritis SK.

Cancer. 2014 Jun 1;120(11):1713-24. doi: 10.1002/cncr.28623. Epub 2014 Feb 27.

9.

Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center.

Gren LH, Lamerato LE, Wright P, Marcus PM.

Rev Recent Clin Trials. 2015;10(3):194-9. Review.

PMID:
26238206
10.

Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.

Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):187-93. Review.

PMID:
26435288
11.

Evaluating a national dissemination approach: The National Cancer Institute's clinical trials education program.

Solomon FM, Thakkar S, Zambon A, Eckstein DS, Michaels M, Johnson L, Squiers L.

J Cancer Educ. 2009;24(1):49-57. doi: 10.1080/08858190802664818.

PMID:
19259866
12.

Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening.

Heuvelmans MA, Vliegenthart R, Oudkerk M.

J Thorac Imaging. 2015 Mar;30(2):101-7. doi: 10.1097/RTI.0000000000000135. Review.

PMID:
25635703
13.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
14.

The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.

Reich JM, Kim JS.

AJR Am J Roentgenol. 2015 Aug;205(2):278-9. doi: 10.2214/AJR.14.13945.

PMID:
26204275
15.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
16.

Two randomized screening trials with prostate cancer mortality, two interim results: a consideration of usual-care window in screening trials.

Song Y.

Contemp Clin Trials. 2010 Jul;31(4):378-80. doi: 10.1016/j.cct.2010.04.005. Epub 2010 May 9.

PMID:
20450987
17.

Absolute numbers of lives saved and overdiagnosis in breast cancer screening.

Junod B, Spinosa JP.

J Med Screen. 2010;17(2):103; author reply 103. doi: 10.1258/jms.2010.010059. No abstract available.

PMID:
20660442
18.

Physician Data Query (PDQ(R)) update.

[No authors listed]

J Natl Cancer Inst. 2012 May 2;104(9):655-6. doi: 10.1093/jnci/djs231. Epub 2012 Apr 18. No abstract available.

PMID:
22517987
19.

Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial.

Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J.

J Clin Oncol. 2005 Dec 1;23(34):8730-8.

PMID:
16314633
20.

Cancer Models and Real-world Data: Better Together.

Kim JJ, Tosteson AN, Zauber AG, Sprague BL, Stout NK, Alagoz O, Trentham-Dietz A, Armstrong K, Pruitt SL, Rutter CM; Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium.

J Natl Cancer Inst. 2015 Nov 3;108(2). pii: djv316. doi: 10.1093/jnci/djv316. Print 2016 Feb.

Supplemental Content

Support Center